Macquarie Group Ltd. boosted its position in shares of Accuray Incorporated (NASDAQ:ARAY) by 46.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,810 shares of the medical equipment provider’s stock after buying an additional 2,487 shares during the quarter. Macquarie Group Ltd.’s holdings in Accuray were worth $27,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of ARAY. Legal & General Group Plc grew its position in shares of Accuray by 7.2% in the 4th quarter. Legal & General Group Plc now owns 1,463,841 shares of the medical equipment provider’s stock worth $4,992,000 after buying an additional 97,741 shares during the period. Metropolitan Life Insurance Co. NY grew its position in shares of Accuray by 343.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 28,917 shares of the medical equipment provider’s stock worth $99,000 after buying an additional 22,393 shares during the period. MetLife Investment Advisors LLC grew its position in shares of Accuray by 34.8% in the 4th quarter. MetLife Investment Advisors LLC now owns 42,251 shares of the medical equipment provider’s stock worth $144,000 after buying an additional 10,915 shares during the period. Candriam Luxembourg S.C.A. grew its position in shares of Accuray by 18.4% in the 4th quarter. Candriam Luxembourg S.C.A. now owns 82,853 shares of the medical equipment provider’s stock worth $283,000 after buying an additional 12,853 shares during the period. Finally, Squarepoint Ops LLC purchased a new stake in shares of Accuray in the 4th quarter worth about $282,000. Institutional investors own 80.24% of the company’s stock.

A number of analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Accuray from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. BidaskClub raised shares of Accuray from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $5.13.

In related news, CEO Joshua Levine sold 6,604 shares of the company’s stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total value of $29,982.16. Following the transaction, the chief executive officer now owns 1,033,593 shares in the company, valued at approximately $4,692,512.22. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 3.40% of the company’s stock.

NASDAQ:ARAY opened at $4.10 on Monday. The stock has a market capitalization of $360.31 million, a PE ratio of -14.64 and a beta of 2.07. Accuray Incorporated has a 1-year low of $3.16 and a 1-year high of $5.40. The company has a current ratio of 1.71, a quick ratio of 1.00 and a debt-to-equity ratio of 2.97.

Accuray (NASDAQ:ARAY) last announced its quarterly earnings results on Tuesday, January 22nd. The medical equipment provider reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.03. The company had revenue of $102.32 million for the quarter, compared to analysts’ expectations of $104.01 million. Accuray had a negative net margin of 5.74% and a negative return on equity of 42.74%. During the same quarter in the previous year, the business posted ($0.06) EPS. On average, analysts forecast that Accuray Incorporated will post -0.16 EPS for the current fiscal year.

WARNING: “Accuray Incorporated (ARAY) Position Raised by Macquarie Group Ltd.” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/accuray-incorporated-aray-position-raised-by-macquarie-group-ltd/2980694.html.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Read More: Why investors pay attention to retained earnings

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.